Dyslipidemia Drugs Market Growth Projected to be Negative Due to Depleting Profit Margins of Major Players

The occurrence of cholesterol abnormalities has been on the rise for the past few years – the occurrence of dyslipidemia, a chronic metabolic syndrome, characterized by an increase in the level of plasma triglycerides, a dip in levels of lipoproteins as well as low-density lipoprotein composition. Given the progressive rise in the burden of dyslipidemia on healthcare agencies because of its high mortality and morbidity rate, healthcare agencies are relying on drugs to bring dyslipidemia under control.

Read More: http://www.transparencymarketresearch.com/dyslipidemia-market.html

0 rating(s) (0 ø)
Views: 32

All rights reserved

• This document may not be used, copied nor changed without explicit consent of the author.
Copyright Icon
The maximum length of a comment is 1000 characters.
The maximum length of an alias is 30 characters.
Please enter a comment.
Please insert a valid comment!